1. Getting the word out. Safi has made the time to educate Wall Street. This continues with another conference (BIO..) next week. 2. Large Hedge Fund exposure and low float - just look at the bid/ask and you can see how easy it is to move this stock. 3. Company is holding an analyst day in NY at the end of March. Great timing as the news flow will begin to get interesting. 4. Company has said to expect an update on Elesclomol at a conference in early summer - there is only one...ASCO. This stock will trade higher in anticipation of positive ASCO news. 5. Additional milestone payments from GSK. 6. Initiation of new trials against other forms of cancer susceptible to oxidative stress...prostate, breast, pancreatic just to name a few of the possibilities. 7. End of 08 - trial enrollment completed and results released on secondary endpoint...primary endpoint will take roughly 12 months longer to obtain data (showing this company has the leadership and experience to position itself in the most favorable way and, by default, increase shareholder value).
There is more but IMHO this in and of itself will move this stock another 50%+ this year.
Remember, SNTA retains 40-50% royalties in the US on Elesclomol and double digit royalties ex-US.
This is an exciting time to be a SNTA shareholder and at these prices I consider it a gift.